|
Market Closed -
NYSE
23:00:00 27/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 2.530 USD | +2.02% |
|
-1.17% | +40.56% |
Company Valuation: Protalix BioTherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 199.8 | - | - |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 38.04% | - | - |
| Enterprise Value (EV) | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 199.8 | 199.8 | 199.8 |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 38.04% | 0% | 0% |
| P/E | -1.34x | -4.42x | 19.8x | 47x | -22.5x | 10.5x | 50.6x | 127x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | -0.8x | 0x | -0x | -0.6x | -2.1x |
| Capitalization / Revenue | 0.99x | 1.46x | 1.98x | 2.59x | 2.74x | 2.43x | 3.01x | 2.9x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.43x | 3.01x | 2.9x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | 0x | -0x | 8.85x | 77.2x | 177x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.62 | -0.31 | 0.09 | 0.04 | -0.08 | 0.24 | 0.05 | 0.02 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.35 | 47.64 | 65.49 | 53.4 | 52.74 | 82.16 | 66.48 | 68.82 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.46 | -13.01 | 10.46 | 3.917 | -5.5 | 22.59 | 2.588 | 1.131 |
| Net income 1 | -27.58 | -14.93 | 8.312 | 2.932 | -6.604 | 19.63 | 3.794 | 1.518 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 0.832 | 1.370 | 1.780 | 1.880 | 1.800 | 2.530 | 2.530 | 2.530 |
| Nbr of stocks (in thousands) | 45,557 | 50,666 | 72,952 | 73,634 | 80,421 | 80,572 | - | - |
| Announcement Date | 3/31/22 A | 2/27/23 A | 3/14/24 A | 3/17/25 A | 3/18/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 10.33x | - | - | - | 200M | |
| 37.58x | 13.15x | 27.92x | 0.53% | 1,140B | |
| 38.98x | 6.55x | 18.43x | 2% | 641B | |
| 37.5x | 8.41x | 17.39x | 2.4% | 507B | |
| 21.33x | 5.19x | 12.91x | 2.53% | 383B | |
| 102.5x | 5.75x | 24.67x | 2.42% | 347B | |
| 21.61x | 5.64x | 13.85x | 2.84% | 293B | |
| 22.44x | 4.53x | 12.94x | 1.95% | 266B | |
| 28.21x | 7.23x | 12.94x | 2.27% | 240B | |
| -46.25x | 7.08x | 27.47x | 2.08% | 197B | |
| Average | 27.42x | 7.06x | 18.73x | 2.11% | 401.4B | |
| Weighted average by Cap. | 35.01x | 8.33x | 20.42x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PLX Stock
- Valuation Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
